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Summary.-Serum immunoglobulin levels were measured in 105 patients with
untreated Hodgkin's disease (HD) and 80 with non-HD lymphomas.
Significant increases in IgG and IgE occurred in the whole HD group. When com-
pared with the histological types of HD, increases of IgG, IgA and IgE were seen in
nodular sclerosis and of IgE alone in mixed-cellularity and lymphocyte-predominant
types. In relation to the stage of disease spread, increases of IgG, IgA and IgE
occurred in Stages II and III, while in Stage IV, although IgE was raised, IgM in
males and IgD fell significantly.
Paired serum samples taken 10-14 months apart showed falls of IgM and IgD after
radiotherapy, and of all Ig classes except IgD after chemotherapy.
Decreased levels of IgM in females, IgG and IgA were found in the non-HD
lymphomas. When analysed in terms of lymphnode histology, decreased IgG, IgA,
IgM and IgE occurred in well differentiated lymphocytic lymphomas, decreased IgA
alone in poorly differentiated lymphocytic lymphomas and decreased IgD in nodular
types of lymphoma.
IN this study the serum immuno-
globulin (Ig) concentrations in patients
with Hodgkin's disease (HD) are related
to the stage of disease, the histological
subtype and the effect of treatment. This
has been done in order to better under-
stand the striking increases of both IgE
(Waldmann et al., 1974; Amlot & Green,
1978) and JgD (Corte et al., 1977) which
have recently been described in this
disease. Whereas the role of IgE in imme-
diate allergic reactions is well established,
little is known about the function of IgD.
The incidence of atopy in HD does not
differ from normal, and other stimuli
which lead to hypergammnaglobulinaemia
E, such as parasitic infestation and chronic
skin disease, have not been found in
patients with HD to account for the raised
levels of IgE (Amlot & Green, 1978).
Hypergammaglobulinaemia with the
impaired cell-mediated immunity seen in
HD (Miller, 1962) has been attributed to
increases in IgG (McKelvey & Fahey,
1965). Decreased levels of IgM and IgA
have been found in HD (Goldman &
Hobbs, 1967) but these findings have not
been confirmed by studies on untreated
patients (Waldmann et al., 1974; WVagener
et al., 1976).
Patients with non-HD lymphomas have
also been examined to compare with HD,
and also to correlate with the different
histological types (Rappaport, 1966). The
non-HD lymphomas are a diverse group
both histologically and biologically.
Although the hypogammaglobulinaemia
found in these lymphomas (Miller, 1962)
seems in keeping with a process that in-
filtrates and replaces the lymphoid sys-
tem, it has yet to be established that this
is a feature of all non-HD lymphomas.
PATIENTS AND METHODS
Hodykin's disease (HD). 105 patients were
studied before either treatment or splen-
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ectomy. Lymphnode histology accorded with
the Rye recommendations (Lukes & Butler,
1966). The extent of their disease was staged
by the Ann Arbor system (Carbone et al.,
1971) which included laparatomy and splen-
ectomy in 55. Patients who underwent
splenectomy were 10/16 in Stage I, 15/19 in
Stage II, 23/41 in Stage III and 7/29 in
Stage IV. The mean age ofthe HD group was
40 years, with a harmonic mean of 32 and a
range of 13-81.
The effect of treatment was followed in 2
groups of patients by paired samples of blood
taken at presentation and 10-14 months later.
Twenty-two ofthese patients were treated by
radiotherapy wNith an upper mantle field on
15, inverted Y field in 2 and total nodal
irradiation (TNI) in 5 (Kaplan, 1966). A
minimum of 3500 rad was delivered over 4-5
weeks, with an interval of 2 weeks between
upper mantle and inverted Y fields in patients
treated by TNI. A second group of 35
patients was treated with chemotherapy and
received either the MOPP regime (De Vita
et al., 1970), or the MVPP regime (Nicholson
et at., 1970).
Non-HD lymphomas.-80 patients were
studied before treatment. Lymphnode hist-
ology was classified according to Rappaport's
system (1966), and simplified into 4 cate-
gories: (i) 7 well differentiated diffuse lymph-
omas and 9 chronic lymphatic leukaemias
(DLL/CLL), (ii) 18 nodular lymphocytic
lymphomas and 3 nodular mixed histiocytic/
lymphocytic types (NLL), (iii) 24 poorly
differentiated diffuse lymphocytic lympnomas
(PDLL) and (iv) 13 diffuse histiocytic lymph-
omas (DHL). Six patients had histologies
which did not fall into these categories, and
included 1 leukaemic reticuloendotheliosis,
1 Burkitt-like lymphoma, 1 angioblastic
lymphadenopathy, 1 immunoproliferative
small-intestinal disease and 2 primary in-
testinal lymphomas of Mediterranean origin.
The mean age of the non-HD group Nas 57
years, with a harmonic mean of 51 and a
range of 15-81.
Atopic history.-Patients and controls were
asked about a history of allergic symptoms:
asthma, hay fever, perennial rhinitis, house-
dust allergy, urticaria or eczema. A history of
drug reactions was not included as an atopic
manifestation.
Controls consisted of 250 subjects from
blood donors, dental outpatients and labora-
tory personnel. Their mean age was 37 years,
with a harmonic mean of 31 and a range of
17-74.
Blood samples were collected in the morn-
ing, allowed to clot in glass at room tem-
perature and stored at -20°C until assayed.
Immunoglobulin measureement. IgG, IgA,
IgM and IgD were measured by radial
immunodiffusion (Mancini et al., 1966).
Specific antisera to IgG, A and M were ob-
tained from the Department of Experimental
Pathology, Birmingham, and their specificity
confirmed by immunoelectrophoresis against
whole serum, and against purified myeloma
proteins. IgD was measured by commercially
available plates (Partigen Hoechst Ltd,
Middlesex). The lower limit of sensitivity was
20 iu/ml for IgG, A and M and 10 iu/ml for
IgD, using standards BSW 67/99 for IgG, A
and M, and BRS 67/37 for IgD, kindly pro-
vided by the National Institute for Biological
Standard and Control, Holly Hill, London.
Test samples were always diluted to within
the range of the standards.
IgE was measured by a double-antibody
radio-immunoassay described elsewhere
(Amlot & Green, 1978). Throughout this
paper, immunoglobulin levels are presented
as international units (iu)/ml but these may
be converted as follows: 1 iu ofIgG= 80-4 ,ug;
1 iu of IgA=14-2 Mug; 1 iu of IgM=8-47 tg;
1 iu of IgD= 1-41 jtg and 1 iu of IgE =2-4 yug.
Statistical analysis. Grouped data are ex-
pressed as geometric means, since Ig levels
show a log-normal distribution, and logarith-
mic transformation ofdata was used through-
out for statistical analysis. A non-parametric
method was used which allowed multiple
comparisons against a single control (Dunnett,
1964). IgM was analysed separately in males
and females because of the known sex
difference in levels of this immunoglobulin.
RESULTS
The immunoglobulin (Ig) levels in
Hodgkin's disease (HD) and in non-HD
lymphomas compared with controls are
shown in Table I. In HD, there were sig-
nificantly raised IgG and IgE levels, a
non-significant increase in IgA and near-
normal IgM and IgD levels. Patients with
non-HD lymphomas had significantly
decreased levels of all major Ig classes,
except IgM in males. Only IgE in atopic
patients with non-HD lymphomas were
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Hodgkin's Non-HD
Contirols dlisease lymplhomas
117t 142** 90**
(54-25f))t (51-:392) (19-416)
III 130 86*
(44-278) (28-605) (11-668)
155 169 117*
(57-423) (44-647) (24-562)
116 118 100
(38-352) (24-644) (12-808)
14 11 9
(0-140)§ (0-175) (0-220)
13 68** 17
(0-150 § (0-200,000) (0-4500)
181 266* 32**
(16-3200)§ (8-23,000) (7-170)
t Figures are geometric means of Ig in itu/ml.
I Figures in parentlheses for IgG, A andl M\1 are
geom. mean + 2 s.d.
§ Figures in parentheses for Igi), an(l IgE are
anges.
*P = <0 05; **JP= <0 01. See P'atients and
Mfethodls.
significantly decreased of the minor Ig
classes.
The distributions of Ig levels in HD and
non-HD lymphomas are shown in Fig. 1.
The log-normal distribution of IgG, A and
M in controls allows comparison with the
patient groups on a scale ranging from
values below 2 standard deviations from
the control geometric mean to greater
than 2 standard deviations above. Both
IgE and IgD have non-Gaussian distribu-
tions even on a log scale, with a bias to-
wards low and undetectable values. The
distribution of IgD is not shown. The
marked shift in the distribution of IgE
levels is apparent.
Ig levels in the histological subtypes of HD
(Table II)
When compared with controls, signifi-
cantly raised IgG and IgA levels only
occur in the nodular sclerosing (NS) type
of HD. Excluding atopics, raised levels of
IgE occur in all types of HD except the
lymphocyte-depleted form. In atopic sub-
jects with HD, there was no significant
TABLE II. Immunoglobulin levels (iu/ml)
in histological subtypes of HD
Histological subtype of HDt
LP NS INIC LD
IgClass Controls (n=15) (n=26) (n=43) (n='21)
G 117 145 166** 133 138
A Ill 123 176** 116 118
M Female 155 139 170 168 182
(n=4) (n= 13) (n= 17) (n=7)
Male 116 78 163 131 92
(n=11) (n=13) (n=26) (n=14)
D 14 20 22 9 7
E Non-
atopic
Atopic
13
(n= 160)
183
(n= 76)
89** 292** 52** 13
(ii = 8) (n = 25) (n = 39) (n= 17)
173 285 202 426
(n=7) (n=1) (n=4) (n=4)
LP: Lymplhocyte predominant; NS: nodular
sclerosis; AIC: mixe(l celltilarity; LD: lymphocyte
dlepleted.
** P< 0-01 compare(d xith controls.
difference in IgE level compared with
atopic controls on the basis ofhistology.
It is worth noting that IgD levels are
lower in the worst types of histology:
mixed cellularity and lymphocyte de-
pleted.
Ig levels and spread of HD (Table III)
Raised levels of IgG, IgA and IgE
occurred in Stages II and III when com-
pared with controls. In Stage IV, levels of
IgE were raised significantly but IgM and
TABLE III. Jmmunoglobulin levels (iu/ml)
in stages of HD spread
Stage of HD
I II III IV
Tg Class Controls (n = 16) (n = 19) (n = 41) (n = 29)
G 117 132 166** 146** 129
A l1l 122 165* 147* 105
M Female 155 155 237 164 140
(n=5) (n=8) (n=17) (n= II)
Male 116 105 156 125 74**
(n=ll) (n=11) (n=24) (n=17)
D
E Non-
14 19 18 14 5*
atopic 13 41 79** 86** 52**
(n= 160) (n= 12) (n= 13) (n=37) (n= 27)
Atopic 183 91 360 324 198
(n=76) (n=4) (n=6) (n=4) (n=2)
Legend as in Table II.
* P<0-05; ** P<0-01, compare(d with conitrols.
TABLE I. JImmunoglobulin concentrations
in controls, Hodgkin's disease and non-
HD lymphomas
IgG
IgA
IgAl Female
AMale
IgD
IgE Non-atopic
Atopic
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Fie-. 1.--Distribution of IgG, A, Al an(d E in lymplhomas compared wxith controls. The hiistogram
(lemonstrates thie percentage of patients falling -vitlhin increments of I standiard deviation (s.d.)
based on the log-normal dlistribution of the control poptulation. Thlus the percentage of patients
wNhich fall within eachl of these limits is charted: less than 2 s.d. below the respective geometric
mean (gX); between - 2 s.d. and -s.d(.; between -s.(. and the gX; between gX aind 1 s.d. above
the gX; and finally more than 2 s.d. above the gX. The barred line indicates lhow the normal control
population distribtutes itself against its own figures for standard dev iationi from gX on a log-normal
basis. For example, it can be seen that 36°o ofnon-atopic HD patients have IgE levels greater than
2 s.d. from the gX compared with -20/ of the normal controls and 5% of the non-HD lympliomas.
It should be noted that 2 s.d. belowN tlle gX for IgE in noni-atopics falls belowv zero.
IgD fell. Again there was no difference in
IgE levels of atopics with HD.
Pathological staging by splenectomy
and laparotomy frequently reveals more
extensive disease than was apparent
clinically, so comparison was made be-
tween clinically and pathologically staged
patients to see whether there were differ-
ences in Ig levels between the two groups
(Table IV). Significantly lower levels of
IgD werefoundin clinically staged patients
with Stage III and IV disease than in their
pathologically staged counterparts, other-
wise Ig levels were similar in the two forms
of staging. Naturally, and as a matter of
therapeutic policy, patients with clinically
apparent Stage IIIB and IV disease were
not subjected to splenectomy, and this
would suggest a more advanced disease
than in their pathologically staged coun-
terparts who had to be submitted to
laparatomy in order to establish either of
these stages. The progressive fall in IgD is
compatible with more advanced disease.
The symptomatic state of the patient
with respect to A or B classification made
no difference to Ig class level, except
where NS histology and B symptoms
concurred. Significantly greater IgE levels
occurred in the 9 symptomatic (B)
T
HODGKIN'S DISEASE
NON-HD LYMPHOMAS
NORMAL CONTROLS
c
._
0 cr
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TABLE IV. Comparison ofIg levels (iu/ml) in clinically andpathologically stagedpatients
with HD
Stage ]
(Thuil. F
Ig Class (n = 6) (n
G 145 1
A 120 1
AlI Female Not analyv,
Mllale 117
1)
E, Non-atopie
* P= <0.05.
15
23
I Stage II Stage III
j-
),atI. Clin. Patlh. Clin. Path.
= 10) (n = 4) (n = 15) (I- =18) (n= 23)
L26 182 162 166 135
L23 145 170 158 126
4able 372 204 138 200
95 162 155 120 129
21 15 19 8 22*
58 51 91 11 71
Stage IV
A
Clin. Pat}X.
(n = 22) (n = 7)
123 151
98 135
178 93
71 93
3 14*
49 63
patients w%iith NTS histology (1 535 it/nml)
than in the 17 patients without symptoms
(A 121 iu/ml, P < 0 0005 by t test). There
are lower levels of IgD in symptomatic
patients with HD than in asymptomatic
patients, but these pose analytical prob-
lems which are dealt wzith later.
Ig and treatment of HD (Figs. 2 and 3)
All Ig classes showed a downward trend
after radiotherapy (RT) and the decrease
was significant for IgM and IgD. The
interval between the paired samples, the
high incidence of atopy (9/22) and the
lower untreated levels ofIgE, may all have
contributed to the lack of significant
change in this Ig (Amlot & Green, 1 978).
In the chemotherapy group, all Ig
classes except IgD fell significantly. It
must not be forgotten that many of these
patients were rendered asplenic during the
course of their investigation, which in
itself may influence Ig levels, especially
IgM. Within the chemotherapy group,
there were sufficient splenic and asplenic
patients to compare the effects of splen-
ectomy (Fig. 4). Splenectomy had no
effect on the fall of IgM due to chemo-
therapy, but there appeared to be a
"protective" effect on IgG and IgA levels
in splenectomized patients. It should be
pointed out that
RT CT
non-splenectomized
RT CT
"II
200- RT
160..
-8120-
SD 80- NS
CT
p<0.005
200- RT
160
120
.Z 8S I
16 -
CT 14-
12-
10 -
8-
6-
p<0.0005 p<0.0025
4 -
200- RT CT RT - Radiotherapy group
n 22
160 CT - Chemotherapy groul)
n-34
- 1204 TI \Analysis t)y p)aired 'ts test
NS - not significant
.iQ 8 NS p<O.OOO5
FIG. 2. Immunoglobilin levels before an(i
after treatment of H1). Geometric means
+S.e.
280-
240-
200-
160-
120-
80-
NS
m
40-.
Id 2 _
I
p<0.0025 NS p<0.0005
FI. 3. IgD and IgE levels before an(d after
treatment of HD. RT Radiotherapy
(n-= 22). CT Chemotlherapy (n= 34).
Analysis by paired t test. NS not signifi-
cant. Geometric means + s.e.
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2001 Sx non-Sx
1601
120 H
80- NS p<0.0025
200_ Sx
160- _
120
80- NS
non-Sx
p<0.0005
100-
120.
80-
4-
-bo 40_
bx non-a,x
p<0.01 p<o.o25
Sx - splenectomy n=10
non-Sx - patients not splen-
ectomised n=25
Analysis by paired 't' test:
NS - not significant
Fia. 4. Effect of splenectomy in relation to
chemotherapy on Ig lev-els.
patients had more severe diseases (by
virtue of disease already too advanced to
allow splenectomy as a staging procedure)
and this, combined with treatment, may
account for this observation, without the
need to invoke some hypothetical regu-
latory role for the spleen.
Ig levels in non-HD lymphomas (Table V)
All classes of Ig except IgD were sig-
nificantly reduced in the DLL/CLL group
TABLE V. Immunoglobulin levels (iu/ml)
in non-HD lymphomas according to
histology
Classification of non-HD
lymphomas
DLL/
CLLt NLL PDLL DHL
Class Controls (n= 16) (n = 21) (n = 24) (n =13)
117 57** 102 108 90
111 59** 106 73* 109
Female 155 79* III 134 99
(n =6) (n= 14) (n= 12) (n=4)
Alale 116 55** 206 lHI 109
(n=0) (n=7) (n=12) (n=9)
14 15 3** 13 10
E Non-
atopic 13 5* 25 20 19
(n = 16) (n = 16) (n
= 23) (n = 12)
t See Patients and Methods for histologi
categories.
* P < 0-05; * P < 0-01, compared with controls.
ical
compared with controls. The reverse was
found in the NLL group, in whom only
IgD levels were significantly lower. In the
PDLL group, IgA levels alone were re-
duced, but all other classes, and all Ig
classes in DHL, were unaffected. There
were too few atopic patients in the non-
HD group to analyse according to histo-
logical type.
Incidence of undetectable levels of IgD
(< 10 iu/ml)
There are theoretical objections to the
analysis of IgD by the methods used, since
a significant proportion of the subjects
could not be assigned an accurate IgD
level. Thirty one per cent of the controls
had JgD < 10 iu/mI, an observation which
agrees with previous experience with the
same technique (Walzer & Kunkel, 1974).
It is, however, possible to compare the
population of undetectable IgD levels in
the population studied, using Fisher's
exact test.
Thirty-four per cent of patients with
HD and 39%0 of patients with non-HD
lymphomas had undetectable IgD levels.
These are not significantly different from
controls.
HD patients with stages IA, IIA, or
IIIA are considered as having disease
contained within the lymphatic system,
while patients with Stage IV by definition
have spread outside the lymphatic system.
Practically, the occurrence of B symptoms
in Stages I, II or III suggests an inability
on the host's part to contain the disease
within the lymphatic system, and conse-
quently within established irradiation
fields. Therefore in many centres chemo-
therapy has been added to improve the
results of radiotherapy, or has replaced it
(Kaplan & Rosenberg, 1975). It was with
this operational division in mind that IgD
levels of patients with Stage I, II and
IIIA were compared with Stages IIB,
IIIB and IV. In the former group 10/52
(20%) had undetectable IgD levels com-
pared with 26/51 (51O%) of the latter
(P <0.003).
In the non-HD lymphomas, 12/16
Ig
G
A
M
D
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(75%0) of patients with NLL histology,
compared with 16/55 (29%0) ofthe remain-
ing non-HD lymphomas had undetectable
IgD levels (P < 0.003).
]DISCUSSION
This study has clearly shown that
immunoglobulin levels in untreated
patients with HD do not fall until the
disease is widespread (Stage IV) and that
then only 2 Ig classes, IgM and IgD, are
affected. The low IgM values previously
ascribed generally to HD patients (Gold-
man & Hobbs, 1967) have not been found
in untreated patients (Waldmann et al.,
1974; Steidle et al., 1976; Wagener et al.,
1976) except in advanced (Stage IV)
disease (Steidle et al., 1976). In this study,
the contribution of radiotherapy and
chemotherapy to o0W IgM levels has been
shown directly. It is worth noting that
IgM fell to subnormal levels with treat-
ment, wrhile the other Igs did not, em-
phasizing the confusion that can arise
when treated patients are studied initially.
The raised levels of IgD that have been
previously described in patients with HD
(Corte et al., 1977) were not found in this
study. The methodology of the present
study was adequate to measure raised IgD
levels although, as we have seen, it is
insensitive below 10 iu/ml. The non-
CGaussian distribution, and great vari-
ability of IgD levels among healthy con-
trols, makes sampling from small groups
and parametric statistical analysis un-
reliable. An unusually low normal level of
IgD (geom. mean 112 4tg/ml) was found in
Corte's study compared to earlier U.K.
and American studies on healthy controls
(Rowe et al., 1968; Walzer & Kunkel, 1974;
Buckley & Fiscus, 1975). Although this is
probably due to the small number of con-
trol subjects, an alternative explanation
comes from the observation that GCm
allotype can influence IgD levels (Walzer
& Kunkel, 1974). It should be borne in
mind that the relevant Gm allotypes differ
considerably between the U.K. and Italy
(Grrubb, 1970).
Unlike the previous study, however, it
was noted here that the initially normal
IgD levels fell significantly with the
dissemination of HD, and although this is
likely to be a result oflymphoid depletion,
a relationship between factors such as
Gm allotype and resistance or lack of re-
sistance to the spread of HD must be
borne in mind.
The increases in the major immuno-
globulins seen in patients with NS his-
tology have been noted in some studies
(Sailer et al., 1973; Steidle et al., 1976) but
not others (Wagener et al., 1976). The
interpretation of nodular sclerosis as a
pathological entity may play a part here.
In this study, an increase in lacunar cells
per se in involved tissues without a clear-
cut nodular sclerosing pattern was not
included in the NS type, although it is in
some centres.
Whereas the fall in IgM and IgD levels
probably relates to the generalized deple-
tion of normal lymphoid tissue which
occurs in widespread HD and lymphocyte-
depleted histologies, the significance of
the raised Ig levels is less obvious. Patients
with HD are generally more susceptible to
infection with intracellular organisms,
mycoses and viruses, but clinical infection
was not present in this group of patients.
It is tempting to link the hypergamma-
globulinaemia with the well described cell-
mediated immunodeficiency in HD. Those
immunodeficiencv syndromes most simi-
lar; and characterized by hypergamma-
globulinaemia E in the absence of atopy,
are the Wiskott Aldrich syndrome (WAS)
and the Nezelof and Job syndromes
(Buckley & Fiscus, 1975; Dahl et al.,
1976). Severe dermatitis and recurrent
severe pyogenic infections in these syn-
dromes provide obvious sources of stimu-
lation for Ig production which are not
present in HD.
Hypergammaglobulinaemia E in HD
has been attributed to a lack ofthe normal
suppressor mechanisms which control Ig
production (Waldmann et al., 1974). This
hypothesis is not supported by the treat-
ment-induced fall of IgE levels seen in
HD, because in animal studies irradiation
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and cytotoxic drugs augment rather than
diminish IgE levels (Tada, 1975). The par-
ticular association of hypergamma-
globulinaemia E with nodular sclerosis, as
well as raised IgG levels, casts further
doubts upon a deficient suppressor activity
in HD.
In the non-HD lymphomas the previous
reports of hypogammaglobulinaemia were
confirmed. Clear differences between the
histological types emerged from analysis of
their Ig levels. The DLL/CLL group con-
tributed predominantly to the low levels
of the major Ig classes seen in non-HD
lymphomas. The widespread involvement
of the lymphoid system and marrow, with
obliteration of germinal centres in in-
volved nodes, makes it easy to conceive
how antibody responses and Ig production
may be diminlished simply by loss of nor-
mal lymphoid tissue. In contrast, the
NLL group had relatively normal Ig
levels. In this group of lymphomas there is
a distortion buit not a diffuse replacement
of the normal germinal centres within
lymph nodes, and they may continue to
function in the initiation of antibody-
forming cells. Furthermore the disease
was less widespread in NLL than in DLL/
CLL types. In NLL there was a relatively
lowv incidence of marrow involvement
(2/22) and a high incidence of Stage I and
II disease (10/22) compared with the
universal marrow involvement in DLL/
CLL. So little is known about the function
of IgD that it is difficult to interpret the
relevance ofthe abnormally low IgD levels
seen in the NLL group.
Patients with DLL/CLL and NLL
histologies have a relatively long survival
and gradual evolution of disease, com-
pared with the PDLI, and DHL types. In
this study, patients with DLL/CLL and
NLL histologies have a median survival
greater than 24 months (7/37 have died)
compared with a median survival of 5
months in the PDLL and DHL groups
(23/37 have died). The rapid evolution and
relatively short survival of PDLL and
DHL patients may not allow sufficient
time for significant changes in Ig levels.
It is interesting that IgA levels are
decreased in the PDLL group, a subset of
which is characterized histologically by
lymphoblasts. Lymphoblasts arising norm-
ally, as a result of antigenic stimulationi,
migrate from the lymphatic system and
"home" to the small intestine which is the
major site of IgA synthesis (CoNans &
Knight, 1964; Hall & Smith, 1970). It, is
not known whether a similar "homing" by
malignant lymphoblasts occurs, but it
could perturb the normnal sequence of IgA
production. Fifteen out of 24 PIDLL
patients had low IgA levels. Nine of these
15 had massive abdominal disease, of
which 5lhad proven intestinal involve-
ment, while a further 5 had a frank
leukaemic plhase at some time during their
illness. All 7 patients in the PDLL group
who had localized disease (Stage I or II)
had normal IgA levels. Thus "homing" of
malignant lymphoblasts to the intestinal
epithelium could explain why IgA appears
to be affected selectively in disseminated
PDLL.
W e? are grateful to D)r G. A. 1K. AliMseii ai(l I)D
D. R. Turner for tlheir careful classificatiom of
lymphornas seen at Guy's Hospital; to the Depart-
ment of Ra(liothlerapy anidI Oncology ani(i the
Department of Medical Oncology at Guy's Hospital
for allowing uis to study tlheir patients; andl to Mr111F.
House for hiis advice on statistical analysis.
This stu(ly was supported by a grant fromi thle
Cancer Researchi Campaigni.
REFERENCES
A-MLOT, P. L. & GREEN, L. (1978) Atopy ali(1
immulnglohbllini E concentIratioins in Hiodlgkni-'s
dlisease an(1 other lympliomas. Br. -led. J., 1, .327.
BVCKLEY, R. H. & Fiscus, S. A. (1975) Serutm IgD
ain(l IgE concentrations in immuino(leflcienley
diseases. J. Cliti. lI,est. 55, 157.
CARBONE, P. P., KAPLAN, H. S., AlVSSHOFF, K.,
S-MITHERS, 1). WN. & TI7BIANA, A. (1971) Repoirt of
the Committee oni Hodgkini's (lisease staginig
classification. Con)cer Res., 31, 1860.
CORTE, G., FERRARINI, Mr., TONDA, 1. & BARGELLESI,
A. (1977) Inerease(I sertum Igi) coIneni1trationIs inI
patients wvithI Hodgkin's disease. Clini. Exp.
Ilinnoinol., 28, 359.
DAHL, Mt. V., GREEN, W1'. H. & QUTIE, 1'. G. (19716)
Inifection. (lermatitis, increase(1 IgE and imnpaie( Id
Ineuttl)ollill clemotaxis. A rch. Derootol., 112, 1 976.
DE VITA, V. T. SERIPICK, A. A. & CARBONE P'. 1.
(1970) Combiniation chelmotlierapy in the treat-
ment of advanced Hodgkini's (lisease. Ann. Wterni.
Med., 73, 881.
DU--NN-ETT, C. W. (1 964) New tables for multiple com-
parisoni wvitlh a conitrol. Biometrics, 20, 482.IMMUNOGLOBULINS IN LYMPHOMAS 379
GOLDMAN, J. M. & HOBBS, J. R. (1967) The immuno-
globulins in Hodgkin's disease. Immunology, 13,
421.
GOWANS, J. L. & KNIGHT, E. J. (1964) The route of
recirculation of lymphocytes in the rat. Proc. R.
Soc. Lond. (Biol.), 159, 257.
GRUBB, R. (1970) The Genetic Markers of Human
Immunoglobulins. Berlin: Springer Verlag.
HALL, J. G. & SMITH, M. E. (1970) Homing oflymph-
borne immunoblasts to the gut. Nature, 226, 262.
KAPLAN, H. S. (1966) Role of intensive radiotherapy
in the management of Hodgkin's disease. Cancer,
19, 356.
KAPLAN, H. S. & ROSENBERG, S. A. (1975) The
management ofHodgkin's disease. Cancer 36, 796.
LUKES, R. J. & BUTLER, J. J. (1966) The pathology
and nomenclature of Hodgkin's disease. Cancer
Res., 26, 1063.
MANCINI, G., CARBONARA, A. 0. & HEREMANS, J. P.
(1966) Immunochemical quantitation of antigens
by single radial immunodiffusion. Immuno-
chemistr?, 2, 235.
McKELVEY, E. M. & FAHEY, J. L. (1965) Immuno-
globulin changes in disease. J. clin. Invest., 44,
1778.
MILLER, D. G. (1962) Patterns of immunological
deficiency in lymphomas and leukaemias. Ann.
Intern. Med., 57, 703.
NICHOLSON, W. M., BEARD, M. E. J., CROWTHER, D.
& 5 others (1970) Combination chemotherapy in
Hodgkin's disease. Br. Med. J., iii, 7.
RAPPAPORT, H. (1966) In Atlas of Tumour Pathology,
Sect. 3, Fascicle 8. Washington.
ROWE, D. S., CRABBE, P. A. & TURNER, M. W. (1968)
Immunoglobulin D in serum, body fluids and
lymphoid tissues. Clin. Exp. Immunol., 3, 477.
SAILER, D., LUTZ, H. & HARTWICH, G. (1973)
Quantitativer Immunoglobulinbestimmung (G, A,
M) bei Lymphogranulomatoser. Verh. Dtsch. Ges.
Inn. Med., 79, 508.
STEIDLE, C., FATEH-MOGHADAM, A., LAMERZ, R.,
HUHN, D. & ERHART, H. (1976) Immunoglobuline
G, A, M. und E bei Lymphogranulomatose. Munch.
Med. Wschr., 118, 503.
TADA, T. (1975) Regulation of reaginlic antibody
formation in animals. Prog. Allergy, 19, 122.
WAGENER, D. J. T., VAN MUNSTER, P. J. J. &
HAANEN, C. (1976) The immunoglobulins in
Hodgkin's disease. Eur. J. Cancer, 12, 683.
WALDMANN, T. A., BULL, J. M., BRUCE, R. M. & 4
others (1974) Serum immunoglobulin E levels in
patients with neoplastic disease. J. Immunol., 113,
379.
WALZER, P. D. & KUNKEL, H. G. (1974) The correla-
tion of serum IgD concentration with Gm allotype.
J. Immunol., 113, 274.